Pharmacist prescribing to improve kidney care for people with type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a hybrid type 1 effectiveness-implementation pilot randomized controlled trial comparing pharmacist-led prescribing using validated diabetic kidney disease algorithms integrated into a digital health app versus usual care delivered by walk-in, mobile, or virtual clinics. The intervention will be delivered through community pharmacist-led primary care clinics launched across Nova Scotia, where pharmacists can prescribe for chronic conditions. The primary focus is on improving uptake of guideline-directed medical treatments (RAS inhibitors, SGLT2 inhibitors, and nsMRA) among adults with earlier-stage diabetic kidney disease who do not have a primary care provider. Feasibility metrics (implementation and recruitment) and medication initiation rates will be measured to inform larger scale implementation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol)
* Adults who do not have primary care provider,
* Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA

Exclusion Criteria:

* Hypotension
* Type 1 diabetes
* History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA).
* Already receiving all three medications: RASi, SGLT2i, and nsMRA .
* Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m²
* Limited life expectancy of less than 1 year
* Followed by a subspecialty physician (e.g., nephrologist or endocrinologist)
* Unable to give consent

Where it's running

• Dalhousie University
  Halifax, Nova Scotia, Canada Recruiting

Study contacts

• Study coordinator: Jo-Anne Wilson, BSc Pharm, ACPR, MEd, PharmD
• Email: Jo-Anne.wilson@dal.ca
• Phone: 9024886623

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Effects of SGLT2 inhibitors on kidney function in Type 2 diabetes

  This study is testing if the diabetes medication Canagliflozin can help protect kidney function in adults with Type 2 diabetes and early signs of kidney disease.

  Recruiting Phase 4 University of Michigan · Ann Arbor, Michigan · NCT06291155

• New methods for diagnosing and treating type 2 diabetes nephropathy

  This study is testing new ways to diagnose and treat kidney problems in people with type 2 diabetes by using advanced tools and combining different medical approaches.

  Recruiting Chinese PLA General Hospital · Beijing · NCT05888909

• Implementing diabetes treatment guidelines by primary care physicians in the community

  This study is testing whether following new diabetes treatment guidelines can help older adults with diabetes avoid serious heart and kidney problems compared to regular care.

  Recruiting at 13 sites Shanghai Zhongshan Hospital · Suzhou, Jaingsu and 12 other locations · NCT05349955

• Global registry for patients with type 2 diabetes and related conditions

  This study is collecting information from doctors around the world about patients with type 2 diabetes and related health issues to better understand how these conditions are managed and treated.

  Recruiting at 67 sites AstraZeneca · Fortaleza, Ceará and 75 other locations · NCT03549754

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.